Cell Cycle, Apoptosis and Cancer Flashcards Preview

Biochemistry > Cell Cycle, Apoptosis and Cancer > Flashcards

Flashcards in Cell Cycle, Apoptosis and Cancer Deck (49):
1

Quiescent cells (in G0)

May reenter the cell cycle at G1 after stimulation by molecules such as growth factors

Hepatocytes, epithelial cells of the kidney tubules

2

Senescent cells (in G0)

Never able to reenter the cell cycle and are unable to proliferate even in the presence of growth factors

Neurons-will never divide again

3

Labile cells

Never enter G0 and are constantly dividing

Gut epithelium, skin, hair follicles, bone marrow

4

How to fully activate CDK's

Need CDK-activating kinases (CAK)

5

CDK levels during cell cycle

Levels of CDKs are constant throughout the cell cycle

6

Cyclin levels during cell cycle

Levels of individual cyclins vary considerably during cell cycle

7

Phosphorylation of CDKs by CAK does what?

CAK (CDK-activating kinase) fully activates the cyclin-CDK complex

(WEE1 inactivates by phosphorylating)

8

Phosphorylation of CDKs by WEE1 kinase does what?

Inhibits cyclin-CDK activity

(CAK (CDK-activating kinase) activates by phosphorylation)

9

CDC25

A phosphatase that can remove the phosphate group that was put on by WEE1.

This will reactivate the cyclin-CDK complex

10

Cyclin-CDK complex activities can be modulated by what?

CDK inhibitor proteins (CKIs)

11

2 families of CKIs

-CIP/KIP

-INK4

12

CIP/KIP

1 of 2 families of CKIs (CDK inhibitor proteins)

i.e. p27. Inhibit G1 and S phase cyclin-CDK activities by binding to the cyclin-CDK complex and altering the conformation of the active site to render CDK inactive

13

INK4

1 of 2 families of CKIs (CDK inhibitor proteins)

i.e. p15, p16, p18 etc. Inhibit G1 CDKs (4 and 6) by binding to them and preventing CDK4 and CDK6 from associating with cyclin D

14

How to terminate the activity of cyclin-CDK complexes

Degrade the transiently expressed cyclin proteins through regulated proteolysis. Targeting them for this is done via polyubiquitination and catalyzed by ubiquitin ligases.

Specific ubiquitin ligases can also ubiquitinate CKIs and target them for degradation, thereby releasing the inhibition of S phase cyclin-CDK complexes

15

What does p27 do?

Binds to the cyclin-CDK complex and inactivates the kinase activity of CDK

16

Retinoblastoma (RB) protein

Substrate of G1 and G1/S cyclin-CDK complexes

Used as a tumor-suppressor protein b/c it can arrest the cell cycle at the G1 checkpoint

17

Hypophosphorylated form of RB

Binds to E2F transcription factors. This sequesters E2Fs and prevents them from triggering the transcription of cyclin E (a G1/S phase cyclin) and cyclin A (an S phase cyclin)

18

Hyperphosphorylation of RB

Hyperphosphorylation of RB by the G1 and G1/S CDKs releases E2Fs and allow for the transcription of cyclin E to occur so that cells can transit the late G1 checkpoint and enter the S phase

19

What keeps RB (retinoblastoma) protein in the phosphorylated state?

S phase and M phase cyclin-CDK complexes

Degradation of these cyclins during the later stages of mitosis allows for the dephosphorylation of RB for the next round of the cell cycle

20

What does DNA damage do to p53?

DNA damage appears to stabilize another tumor suppressor protein known as p53

21

In the presence of DNA damage, p53 is _____

p53 is phosphorylated and stabilized

It can stimulate the transcription of many genes including p21 (CIP/KIP family of CKI). Inhibition of cyclin-CDKs by p21 can lead to arrest of cells in G1, S and G2 phases

22

If DNA damage is not fixed, then what happens?

Apoptosis

23

Retinoblastoma and the RB protein

Retinoblastoma is a childhood disease.

Tumors develop due to unchecked division of precursor cells in the immature retina.

Hereditary form affects both eyes
Nonhereditary form affects one eye

In the hereditary form, one copy of the RB gene is mutated or lost in every cell, and the cells become predisposed to becoming cancerous. Cancerous cells contain different somatic mutations in the two copies of the RB gene

24

p53 and cancer

More than 50% of all human cancers exhibit mutations in the p53 gene

Metabolic activation of benzo(a)pyrene (in cigarette smoke) makes a potent mutagen. Activated benzopyrene causes mutations in genes such as p53 by G-->T transversion.

Aflatoxin (in moldy grain and peanuts) also induces G-->T transversions in the p53 gene

25

Apoptosis is caused by what?

A cascade of intracellular proteases called caspases

26

Extrinsic pathway

Initiates outside the cell

"death receptor pathway"

Triggered by binding and activation of an external death ligand (i.e. Fas ligand) to its receptor on the plasma membrane

Adaptor proteins containing death domains (i.e. Fasassociated death domain protein (FADD)) bind to intracellular regions of the activated receptor and recruit procaspase-8

Autocatalysts of procaspase-8 generates caspase-8, which then initiates a caspase cascade involving other caspases (3,6,7)

27

Intrinsic Pathway

Triggers apoptosis inside the cell

"mitochondrial pathway"

Triggered by events such as growth factor withdrawal, DNA damage (which increases p53), and cell cycle defects

(Check notes/picture for pathway diagram)

28

Proto-oncogenes

These encode proteins that promote cell growth and division. Tend to be members of sell-signaling pathways, i.e. growth factors, hormone receptors, signal transducers and TF's

Such "gain of function" mutations often appear to be inherited in an autosomal dominant fashion

29

How are proto-oncogenes converted to oncogenes?

Via gain of function mutations

30

Proto-oncogenes and HER2

A point mutation that changes Val to Gln

Oncoprotein: NEU

BREAST CANCER

31

EGF and ligand binding doma-->ocoprotein

Deletion in part of gene

Oncoprotein: EGFRvIII

GLIOBLASTOMA

32

How proto-oncogenes are converted to oncogenes (3 mechanisms)

1. A point mutation

2. Gene amplification

3. Chromosomal translocation: genetic rearrangement (e.g. c-MYC, ABL)
-MYC→Burkitt Lymphoma
-ABL→myelogenous leukemia (CML)

33

Tumor suppressor genes

Even one good copy of a tumor suppressor gene is usually sufficient to provide normal regulation. Therefore, mutations in tumor suppressor genes appear to be autosomal recessive mutations, and both copies of such genes have to be damaged to make the cells prone to the onset of cancer. These mutations are known as "loss of function"

Thus, oncogenesis results when somatic mutations occur in combination with the inheritance of recessive mutations and so both alleles become dysfunctional.

34

Tumor suppressor gene: p53

Monitors checkpoints of cell cycle

Characteristics of Mutated Protein Product: Observed in >50% of all human tumors

35

Tumor suppressor gene: RB

Regulates G1 phase of cell cycle

Characteristics of Mutated Protein Product: Observed in retinoblastoma

36

Tumor suppressor gene: APC

Regulates cell proliferation

Early event that occurs in the progression toward colon cancer

37

Tumor suppressor gene: BRCA1/BRCA2

Plays a role in DNA repair and apoptosis

Inheritance of a mutated BRCA1 gene increases chance of developing breast cancer by the age of 50 by 30x

38

Traits that appear to be common to most tumor cells

1. Self-sufficiency in growth signals (tumor cells don't need external growth factors b/c many oncogene products mimic growth signaling)

2. Evading growth suppressors (resist growth inhibitory signals)

3. Activating invasion and metastasis (tumor masses spawn pioneer cells that invade other regions. Metastases are the cause of 90% of cancer deaths)

4. Enabling replicative immortality (cancer cells continue to express telomerase activity)

5. Inducible angiogenesis (cells in tissue need a nearby blood vessel to get their nutrients. Cancer cells can induce the development of new blood vessels)

6. Resisting cell death (cancer cells appear to be defective in both intrinsic/extrinsic pathways of apoptosis)

7. Deregulating cellular energetics (they can upregulate their GLUT1 glucose transporters)

8. Avoiding immune destruction (they appear to be invisible to the body's T and B lymphocyte immune cells)

9. Tumor promoting inflammation (ROS may accelerate mutagenesis of cancer cells)

10. Genome instability and mutation (mutations lead to faster mutations)

39

Metastatic colon cancer model

"Multihit" model: takes mutations in multiple genes over a period of time for the development of full-blown cancer

Development of metastatic colon carcinoma appears to involve the following events:

1. An early loss of the anaphase-promoting complex (APC) tumor suppressor gene from the long arm of chromosome 5

2. Activation of the K-RAS oncogene (with a Val 12 mutation) on the short arm of chromosome 12

3. Loss of the deleted in colorectal carcinoma (DCC) tumor suppressor gene from the long arm of chromosome 18

4. Loss of the p53 tumor suppressor gene from the short arm of chromosome 17

5. Other events (e.g. stimulated angiogenesis)

40

RAS and cancer

Point mutation changing Glycine → Valine

Result: RAS oncoprotein is perpetually active

41

Recognition domains

Adaptor proteins such as GRB-2 and IRS-1 have special domains known as SH2 domains or PTB domains that recognize and bind to motifs on the receptor that contain phosphorylated tyrosine residues

42

Viral Oncogenesis

It accidentally incorporates an adjacent host proto-oncogene into its genome

43

Fibrosarcomas in chickens

****Rous sarcoma retrovirus (RSV) can cause fibrosarcomas in chickens. The transforming factors introduced by the RSV was v-src, a tyrosine kinase. The v-src gene is the oncogenic form of the normal host proto-oncogene c-SRC

Proto-oncogene: c-SRC
oncogene(mutated): v-src

44

Targeted inhibition of Oncoproteins. What do they use in general?

They target particular oncoproteins with monoclonal antibodies or specific inhibitors

45

Targeted inhibition of Oncoproteins: Herceptin

For breast cancer

Monoclonal antibody (mAb) against HER2/NEU epidermal growth factor (EGF) receptors expressed in the mammary tissue

HER2/NEU are overexpressed

46

Targeted inhibition of Oncoproteins: Erbitux

For colorectal cancer

A monoclonal antibody (mAb) directed against the EGF receptor that is over-expressed in colorectal cancer

47

Targeted inhibition of Oncoproteins: Gleevec

For chronic myelogenous leukemia (CML)

An inhibitor that binds to the active site of the ABL tyrosine kinase and inhibits its activity (prevents phosphorylation). Has little effect on hurting the normal white cells in the blood. Targets an oncoprotein (BCR-ABL) that is unique to cancer cells.

48

G1, G2, G3

G1: fix any DNA damage
G2: verify
G3: ensure chromasomes are good

49

If a cancer destroys all abilities of DNA repair pathways...which principle does this represent?

Mutation in epidermal growth factor...what principle is this?

Genomic instability


Self-sufficiency in growth signals